It is likely that APCs acquire MHC-I bearing tumor antigenic peptides from NLRC5 expressing B16 cells, presumably via the process of ‘trogocytosis’ [255,256], and that such ‘cross-dressed’ APCs induce antitumor immune response more efficiently than APCs processing the antigens of parental B16 cells. The gene discussed is NLRC5; the disease is neoplasm.